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Osteogenesis imperfecta (OI) is a group of genetic heterogeneous connective tissue disorders characterized by
increased bone fragility and susceptibility to fractures. Laboratory diagnosis relies on time-consuming and
cost-intensive biochemical and molecular genetics analyses. Therefore, it is desirable to identify and establish
new diagnostic markers for OI that are reliable, cost-effective and easily accessible. In our study we have
identified the ratio of the urinary pyridinoline cross-links lysyl-pyridinoline and hydroxylysyl-pyridinoline as a
promising, time- and cost-effective biomarker for osteogenesis imperfecta, that could be used furthermore to
investigate cases of suspected non-accidental injury in infants.
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Osteogenesis imperfecta or “brittle bone disease” (OI) is
a clinically and genetically heterogeneous disorder of
bone matrix formation and remodelling, presenting with
low bone mass, bone fragility and deformity, short stature,
grey or blue sclera, and hearing loss. Its prevalence is
about 1 in 15,000 to 20,000 births [1]. Approximately 90 %
of OI cases are caused by dominant mutations in COL1A1
and COL1A2 resulting in quantitative and/or qualitative
alterations of type I collagen, the major extracellular
matrix component of bone and skin. A proportion of the
remaining 10 % is due to either dominant or recessive
mutations in several noncollagenous genes involved in
the post-translational processing of procollagen I, in
intracellular collagen transport, in osteoblast-specific
signaling or in gene regulation [2].
Diagnosis of OI and identification of the disease-
causing gene is important i) to end the patient’s quest
for the disease causing his or her symptoms; ii) to allow
for prenatal diagnosis, iii) to clarify cases of suspected
“non-accidental injury” or “battered child syndrome”; iv)* Correspondence: Cecilia.Giunta@kispi.uzh.ch
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order to develop new therapeutic approaches. Establish-
ing a specific diagnosis currently relies on biochemical
analysis of collagens secreted by cultured fibroblast
obtained by skin biopsies, and on molecular genetic
analysis of the known OI related genes. The accessibil-
ity of modern genomic sequencing technologies has
reduced the cost of molecular genetic testing, which was
almost prohibitive in the past, due to the large number of
genes, and exons per gene, to be sequenced. However,
the interpretation of the molecular testing often re-
quires biochemical investigations aimed to infer
pathogenecity to the identified sequence variant if it is
not yet reported on specialized mutation data bases
such as the Database of Osteogenesis imperfecta variants
at http://www.le.ac.uk/genetics/collagen/. Therefore, the
cost remains a hurdle in OI diagnostics.
The urinary cross-links lysyl-pyridinoline (LP, or deoxy-
pyridinoline DPD) and hydroxylysyl-pyridinoline (HP, or
pyridinoline PYD) are established biochemical markers of
osteoclastic bone resorption and collagen degradation.
Pyridinolines are formed during fibril formation of type I
and type II collagen in the extracellular matrix. Some
lysyl- and hydroxylysyl-residues in distinct positions in thele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Fig. 1 LP/HP ratios of OI patients, heterozygote carriers and controls
[3]. OI patients with mutations in LEPRE1, CRTAP, SP7/OSX, FKBP10,
WNT1 and IFTM5 show decreased LP/HP ratios compared to
controls. Heterozygous carriers for a SP7/OSX mutation show
slightly decreased ratios; carriers for LEPRE1 and CRTAP mutations
show normal LP/HP ratios. OI patients with mutations in SERPINF1
or BMP1/mTLD have LP/HP ratios within the control range. In
individuals with COL1A1/COL1A2 mutations LP/HP ratios were
normal in 15/24, decreased in 8/24 and increased in 1/24. 6 out
of 8 patients presenting with low LP/HP ratios were aged 0.1-2
years. Error bars indicates standard deviations (SD) or the highest
measured value * (sample size n = 2)
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collagen are oxidised by lysyl oxidase. Subsequently three
of these residues are covalently linked thereby intercon-
necting tropocollagen molecules and stabilizing the
collagen matrix. When bone collagen is degraded, pyri-
dinolines remain as stable degradation products and are
secreted with the urine. Depending on whether or not these
lysyl residues had been hydroxylated prior to crosslinking,
lysyl-pyridinoline (LP) or hydroxylysyl-pyridinoline (HP) is
generated. Although LP and HP values in the urine vary
substantially depending on age and time of sampling, their
ratio is remarkably constant (LP/HP: 0.2 + 0.03) in healthy
individuals at any age [3]. Furthermore, LP/HP ratios are
proven diagnostic tools for genetic disorders of collagen
metabolism such as the kyphoscoliotic type of Ehlers-
Danlos syndrome (EDS VIA) [4].
Since both dominant and recessive forms of OI lead to
abnormal cross-linking chemistry in bone collagen [5],
we hypothesize that the urinary LP/HP ratio may serve
as a diagnostic biomarker for OI.
Methodology
The study was conducted according to the declaration of
Helsinki, and approved by SwissEthics. To test whether
the ratio of urinary pyridinolines LP/HP may be used as
a biomarker for OI, we measured LP and HP cross-links
by automated HPLC [3] in spot urines of 49 genetically
defined OI patients. The study cohort included patients
with mutations in the following genes: COL1A1 or
COL1A2 (n = 24; including 6 patients aged 0.1-24
months), LEPRE1 (n = 8), CRTAP (n = 4), SP7/OSX (n = 1),
BMP1/mTLD (n = 2), SERPINF1 (n = 2), the recurrent
c.-14C > T in IFTM5 (n = 3),WNT1 (n = 1), PLOD2 (n = 1)
and FKBP10 (n = 3), as well as heterozygous carriers for
mutations in LEPRE1 (n = 2), CRTAP (n = 2) and SP7/OSX
(n = 2).
Findings
LP/HP ratios are shown in Fig. 1. Compared to control
LP/HP ratios (0.20 ± 0.03, n = 325) [3], we found (i) mark-
edly decreased LP/HP ratios in OI patients with mutations
in LEPRE1 (mean: 0.11), in CRTAP (mean: 0.106), in
SP7/OSX (0.086) and in IFTM5 (mean: 0.095); (ii) moder-
ately decreased ratios in patients with mutations in
FKBP10 (mean: 0.128), in WNT1 (0.126), as well as in
heterozygous carriers for a mutation in SP7/OSX (mean:
0.128); (iii) normal LP/HP ratios in patients with muta-
tions in SERPINF1 (mean: 0.195), in BMP1/mTLD
(mean: 0.226), and in heterozygous carriers for LEPRE1
(mean: 0.2) and CRTAP (mean: 0.172) mutations. In
patients with COL1A1/COL1A2 mutations (mean:
0.184; n = 24), the LP/HP ratios were normal in 15/24,
decreased in 8/24 and increased in 1/24. 6 out of 8
patients presenting with decreased LP/HP ratios wereaged 0.1-2 years (normal values: 0.172 ± 0.02, age 1-12
months; 0.193 ± 0.03, age 1-3 years) [3].
Bisphosphonate treatment did not influence the ratio
of total urinary pyridinoline cross-links (data not shown).Conclusions
These results identify the urinary pyridinoline ratio LP/
HP as a promising biomarker for some forms of OI. In
particular, it has the potential to detect recessive forms
of OI caused by mutations in the genes LEPRE1, CRTAP,
FKBP10, WNT1 and SP7/OSX, and to discriminate bet-
ween the dominant inherited forms caused by COL1A1/
COL1A2 and IFTM5 mutations, therefore improving the
efficacy of the final diagnosis and reducing the time and
costs of laboratory investigations. Furthermore, the urin-
ary LP/HP ratios might be helpful in investigating cases
of suspected non-accidental injury in babies and infants
aged 2 years and below.
More samples will be needed to establish urinary pyri-
dinolines as a screening tool for OI diagnostics. There-
fore, with this report we hope to attract more cases of
OI with a known genetic defect in order to statistically
validate our preliminary study.
Abbreviations
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Lindert et al. Orphanet Journal of Rare Diseases  (2015) 10:104 Page 3 of 3Authors’ disclosures or potential conflicts of interest
All authors declare that they have no conflicts of interest with the contents
of this article. All authors have read and agreed to the content of the
manuscript and all authors are included on the author list.
Authors’ contributions
CG, MR and UL designed the study and wrote the paper. All authors have
contributed to drafting or revising the article for intellectual content, and
have approved the final version of the manuscript.
Acknowledgements
We are most grateful to Profs. B. Steinmann, I. Kennerknecht, F. Rutsch, Ch.
Netzer, VL. Ruiz-Perez, N. Elcioglu, M. Janner, B. Steiner, S. Temtami, M. Aglan,
D. Sillence, EM. Abdalla, for contributing to this study with patient samples.
We thank Angelika Schwarze and Christine Plüss for expert technical
assistance, and Dr. Sofie Symoens, Center for Medical Genetics Ghent, for
communicating molecular genetic findings of some patients.
Funding sources
The work was supported by the Swiss National Science Foundation (SNF
Grant Nr. 310030_138288) and the Gottfried und Julia Bangerter-Rhyner-
Stiftung to CG and MR.
Author details
1Division of Metabolism, Connective Tissue Unit, University Children’s
Hospital Zurich and Children’s Research Centre, Zurich, Switzerland. 2Clinic
for Endocrinology, Diabetology and Metabolism, University Hospital, Basel,
Switzerland. 3Center for Molecular Diseases, Lausanne University Hospital,
Lausanne, Switzerland.
Received: 18 June 2015 Accepted: 30 July 2015
References
1. Marini JC. Nelson textbook of pediatrics. Philadelphia: Saunders;
2004. p. 2336–38.
2. Lindert U, Weis MA, Rai J, Seeliger F, Hausser I, Leeb T, et al. Molecular
Consequences of Defective SERPINH1/HSP47 in the Dachshund Natural
Model of Osteogenesis Imperfecta. J Biol Chem. 2015. doi:10.1074/
jbc.M115.661025.
3. Kraenzlin ME, Kraenzlin CA, Meier C, Giunta C, Steinmann B. Automated
HPLC assay for urinary collagen cross-links: effect of age, menopause,
and metabolic bone diseases. Clin Chem. 2008;54(9):1546–53.
doi:10.1373/clinchem.2008.105262.
4. Steinmann B, Eyre DR, Shao P. Urinary pyridinoline cross-links in Ehlers-Danlos
syndrome type VI. Am J Hum Genet. 1995;57(6):1505–8.
5. Eyre DR, Weis MA. Bone collagen: new clues to its mineralization
mechanism from recessive osteogenesis imperfecta. Calcif Tissue Int.
2013;93(4):338–47. doi:10.1007/s00223-013-9723-9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
